Literature DB >> 8131851

Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia.

Y Adachi1, G N Pavlakis, T D Copeland.   

Abstract

SET, the translocation breakpoint-encoded protein in acute undifferentiated leukemia (AUL), is identified as a 39-kDa phosphoprotein found predominantly in the cell nuclei [1994, J. Biol. Chem. 269, 2258-2262]. SET is fused to a putative oncoprotein, CAN, in AUL and is thought to regulate the transformation potential of SET-CAN by its nuclear localization and phosphorylation. We investigated in detail the in vivo phosphorylation of SET. Phosphorylation of SET occurred in all human cell lines examined in vivo, primarily on serine residues. Endoproteinase Glu-C digestion of phosphorylated SET yielded two phosphopeptides. By radiosequencing, we identified the in vivo phosphorylation sites of SET as Ser9 and Ser24. The surrounding sequences of Ser9 and Ser24 contained an apparent consensus site sequence for protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8131851     DOI: 10.1016/0014-5793(94)80144-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Recombinant human granzyme A binds to two putative HLA-associated proteins and cleaves one of them.

Authors:  P J Beresford; C M Kam; J C Powers; J Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET.

Authors:  Jean Paul ten Klooster; Ingrid v Leeuwen; Nina Scheres; Eloise C Anthony; Peter L Hordijk
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

3.  Phosphorylation by casein kinase 2 regulates Nap1 localization and function.

Authors:  Meredith E K Calvert; Kristin M Keck; Celeste Ptak; Jeffrey Shabanowitz; Donald F Hunt; Lucy F Pemberton
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

4.  Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.

Authors:  Lisette Arnaud; She Chen; Fei Liu; Bin Li; Sabiha Khatoon; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FEBS Lett       Date:  2011-07-28       Impact factor: 4.124

5.  Inhibition of protein phosphatase 2A activity by PI3Kγ regulates β-adrenergic receptor function.

Authors:  Neelakantan T Vasudevan; Maradumane L Mohan; Manveen K Gupta; Afshan K Hussain; Sathyamangla V Naga Prasad
Journal:  Mol Cell       Date:  2011-03-18       Impact factor: 17.970

6.  Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus-associated non-Hodgkin's lymphoma.

Authors:  V Tarantul; A Nikolaev; H Hannig; B Kalmyrzaev; I Muchoyan; V Maximov; V Nenasheva; V Dubovaya; G Hunsmann; W Bodemer
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

7.  Upregulation of SET expression by BACE1 and its implications in Down syndrome.

Authors:  Xiaozhu Zhang; Yili Wu; Xiaoling Duan; Wei Chen; Haiyan Zou; Mingming Zhang; Shuting Zhang; Fang Cai; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.590

8.  Protein phosphatase 2A activity affects histone H3 phosphorylation and transcription in Drosophila melanogaster.

Authors:  Scott J Nowak; Chi-Yun Pai; Victor G Corces
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

9.  Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Authors:  Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Steve Roof; Jason G Harb; Greg Ferenchak; Ann-Kathrin Eisfeld; James R Van Brocklyn; Roger Briesewitz; Sahar A Saddoughi; Kyosuke Nagata; Robert Bittman; Michael A Caligiuri; Omar Abdel-Wahab; Ross Levine; Ralph B Arlinghaus; Alfonso Quintas-Cardama; John M Goldman; Jane Apperley; Alistair Reid; Dragana Milojkovic; Mark T Ziolo; Guido Marcucci; Besim Ogretmen; Paolo Neviani; Danilo Perrotti
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

Review 10.  Anp32e (Cpd1) and related protein phosphatase 2 inhibitors.

Authors:  Tomás A Santa-Coloma
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.